Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 80 years old and have been diagnosed with chronic hypersensitivity pneumonitis, an interstitial lung disease (ILD) linked to a connective tissue condition (such as rheumatoid arthritis, systemic sclerosis, or mixed connective tissue disease), or an undifferentiated ILD.
- You have been on a stable dose of certain immune-suppressing medications (such as prednisone, mycophenolate mofetil, mycophenolate sodium, and/or rituximab) for at least 3 months.
- A recent lung scan (within the past year) shows signs of pulmonary fibrosis (scarring in the lungs).
- Your lung function test results meet certain minimum levels for two specific measurements (confirm with trial site for exact values).
Who may not be able to join:
- You have ever taken or are currently taking an FDA-approved anti-fibrotic (anti-scarring) medication for your lungs.
- Your lung scan shows more emphysema (a different type of lung damage) than fibrosis (scarring).
- You are pregnant or planning to become pregnant during the study.
- You have a reason why you cannot have an MRI scan.
- You have a reason why you cannot receive a contrast dye used during certain MRI scans.
- You have had a high level of radiation exposure from research studies in the past year (confirm with trial site).
- You have chronic kidney disease with significantly reduced kidney function (confirm with trial site).
- You are being treated with medication for a serious lung blood pressure condition called pulmonary hypertension.
- You have had a respiratory infection in the past 6 weeks.
- You have smoked anything in the past 6 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sydney Montesi, MD, Massachusetts General Hospital
Phone: 617 724 4030
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Development of progressive pulmonary fibrosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.